Reimbursed midostaurin became available on the Australian Pharmaceutical Benefits Scheme (PBS) from December 2018, with approval based on the pivotal RATIFY trial in which 707 patients aged 18–59 years with newly diagnosed FLT3 mutation positive AML were randomized (between 2008 and 2011) to either midostaurin or placebo in combination with intensive induction and consolidation therapy. Here, FLT3 is linked to acute myeloid leukemia.